Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 31;15(4):1996-2001.
doi: 10.21037/jgo-24-326. Epub 2024 Aug 1.

Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer

Gareth Pollin  1 , Gwen A Lomberk  1 , Angela J Mathison  1 , Michael T Zimmermann  1 , Raul Urrutia  1
Affiliations
Editorial

Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer

Gareth Pollin et al. J Gastrointest Oncol. .
No abstract available

Keywords: MRTX1133; Pancreatic ductal adenocarcinoma (PDAC); RASopathy; inhibitors; mutant KRAS.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-326/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Prevalence and heterogeneity of mutant KRAS in pancreatic cancer. (A) Bar chart illustrating the prevalence of mutant KRAS in pancreatic cancer patients in GENIE (n=6,410) and GDC (n=281) as of April 2024. (B) Pie chart showing distribution of mutant KRAS heterogeneity among pancreatic cancer patients, based on data from the GENIE patient samples. WT, wild-type; GENIE, Genomics Evidence Neoplasia Information Exchange; GDC, Genomic Data Commons.
Figure 2
Figure 2
Structural comparison of KRAS drug binding conformations. All models are Human variations of substrate-bound KRAS. KRAS colored by secondary structure features, helices in blue and strands in yellow; p-loop and hotspots in red; switch-I in pink, switch-II in violet, and ligands in CPK colors for non-carbon atoms and tan for carbon atoms. (A) Non-hydrolysable ATP bound WT KRAS (PDB: 4OBE). (B) GDP bound KRASG12D in complex with YK-8S (8JHL). (C) WT KRAS in complex with BI-2865 (8AZV). CPK, Corey-Pauling-Koltun; ATP, adenosine triphosphate; GDP, guanosine diphosphate; WT, wild-type.
See this image and copyright information in PMC

Comment on

References

    1. Tripathi S, Dsouza NR, Mathison AJ, et al. Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics. Comput Struct Biotechnol J 2021;20:117-27. 10.1016/j.csbj.2021.12.007 - DOI - PMC - PubMed
    1. Tripathi S, Dsouza NR, Urrutia R, et al. Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations. Bioinformatics 2021;37:1367-75. 10.1093/bioinformatics/btaa972 - DOI - PMC - PubMed
    1. Wei D, Wang L, Zuo X, et al. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res 2024;30:655-62. 10.1158/1078-0432.CCR-23-2098 - DOI - PMC - PubMed
    1. Urrutia R, DiMagno EP. Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? Gastroenterology 1996;110:306-10. 10.1053/gast.1996.v110.agast960306 - DOI - PubMed
    1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.2024. Available online: https://gco.iarc.who.int/today. Accessed April 28, 2024.